Figure 2
Age interacted with vaccine to predict neutralizing antibody level (nAB). The relationship between age and nAB was most negative for Janssen recipients, then Pfizer recipients, and not significant for Moderna recipients. This hierarchy of vulnerability to age mirrored the hierarchy of nAB produced at 1-month follow-up irrespective of age (Fig. 1), suggesting that vaccine potency may have conferred protection against the effects of age. Lines and shading represent model-derived estimated means +/− 95% CI for all observed levels of age. These estimates represent the effect of age within vaccine irrespective of follow-up time point, because the three-way interaction between age, vaccine, and time point was not significant.
